Drug intelligence / Profile preview

OI-1

Development stage: Preclinical
Lead developer: Oncoinvent Solutions
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

OI-1 is a monoclonal antibody drug candidate developed by Oncoinvent ASA. It acts as an inhibitor of protein-tyrosine kinase 7 (PTK7), a receptor tyrosine kinase implicated in cancer cell signaling and tumor progression. The primary therapeutic area for OI-1 is oncology, specifically targeting solid tumors. As of the latest update, its highest development status is preclinical[1].

Targets

PTK7 (Protein tyrosine kinase 7)

Beyond the preview

Go deeper on OI-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OI-1.

Explore the full profile